CAR-T cells targeting CD19 and CD22

CAR-T cells targeting CD19 and CD22 refers to a category of bispecific chimeric antigen receptor (CAR) T-cell therapies engineered to simultaneously recognize and bind two distinct B-cell surface antigens, CD19 and CD22. This dual-targeting strategy is designed to mitigate the risk of 'antigen escape,' a common mechanism of resistance in single-target CAR-T therapies (such as those targeting CD19 alone) where tumor cells downregulate or lose the target antigen to evade immune detection. By requiring the loss of two different antigens for escape, these therapies aim to provide more durable clinical responses in B-cell malignancies. A specific example of this platform is **MB-CART2219.1**, an investigational therapy developed by the **University Hospital Tuebingen** with manufacturing support from **Miltenyi Biotec**. MB-CART2219.1 is produced by transducing patient or donor lymphocytes with a lentiviral vector encoding human-derived anti-CD19 (clone M19217-1) and anti-CD22 (clone 16p17) single-chain variable fragments (scFvs). The manufacturing process utilizes the automated **CliniMACS Prodigy** system. MB-CART2219.1 is currently undergoing Phase I clinical evaluation for the treatment of relapsed or refractory B-cell malignancies, including B-cell lymphoma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL), in both adult and pediatric populations.

Other names

CD19/CD22 bispecific CAR-T cellsCD19/CD22 CAR-Tbispecific CD19/CD22 CAR-T cells